Flora Mulkey

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 3

Top Topics

Drug Administration

Ejection Fraction

Radiation Therapy

Early Breast Cancer

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Melanie E Royce, Flora Mulkey, Christy Osgood, Erik W Bloomquist, Laleh Amiri-Kordestani
US Food and Drug Administration Expanded Adjuvant Indication of Abemaciclib in High-Risk Early Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Melanie E Royce, Christy Osgood, Flora Mulkey, Erik Bloomquist, William F Pierce, Arpita Roy, Shyam Kalavar, Soma Ghosh, Reena Philip, Fatima Rizvi, Bronwyn D Mixter, Shenghui Tang, Richard Pazdur, Julia A Beaver, Laleh Amiri-Kordestani
FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (11) (2022)
Flora Mulkey, Marc R Theoret, Patricia Keegan, Richard Pazdur, Rajeshwari Sridhara
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis. Journal for immunotherapy of cancer 8 (1) (2020)